Sugi Predict

Sugi Predict / Compounds / SCHEMBL2390166

SCHEMBL2390166

SCHEMBL2390166

COC(=O)CC[C@H](NC(=O)OC(C)(C)C)C(=O)OC(C)(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ CTSK P43235 9/20 0.47
▸ CTSS P25774 5/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ CA2 P00918 2/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA7 P43166 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ CTSL P07711 1/20 0.40
▸ CTSB P07858 1/20 0.40
▸ CA12 O43570 1/20 0.40
▸ CA14 Q9ULX7 1/20 0.40
▸ POLB P06746 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ PPARG P37231 1/20 0.39
▸ PPARA Q07869 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15418649 1.00 CYP1A2 (0.49) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL28584878 0.94 CYP1A2 (0.43) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL23452709 0.94 CYP1A2 (0.43) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL1317487 0.94 CYP1A2 (0.49) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL2225458 0.94 CYP1A2 (0.49) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL1763873 0.94 CYP1A2 (0.49) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL13570964 0.92 CYP1A2 (0.50) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL13570965 0.92 CYP1A2 (0.50) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL28381396 0.92 CTSK (0.44) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL20732234 0.92 CTSK (0.44) CYP1A2CYP2C9CYP2C19HTTCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001914-A1 MACROCYCLIC PEPTIDES TARGETING KRAS MERCK SHARP & DOHME LLC (US) 2026-01-01 — — US disclosed
EP-4558513-A1 MACROCYCLIC PEPTIDES TARGETING KRAS Merck Sharp & Dohme LLC (US) 2025-05-28 — — EP disclosed
WO-2024200819-A1 PROTEASE INHIBITORS FOR CORONAVIRAL INFECTIONS PROTINHI B.V. (NL) 2024-10-03 — — WO disclosed
EP-4408454-A1 PROTEASE INHIBITORS Protinhi B.V. (NL) 2024-08-07 — — EP disclosed
US-20240051985-A1 METTL3 MODULATORS ACCENT THERAPEUTICS INC (US) 2024-02-15 — — US disclosed
WO-2024020159-A1 MACROCYCLIC PEPTIDES TARGETING KRAS MERCK SHARP & DOHME LLC (US) 2024-01-25 — — WO disclosed
US-20240018110-A1 RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN ALPHA-9 ONCOLOGY INC. (CA) 2024-01-18 — — US disclosed
US-20240018110-A1 RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN ALPHA-9 ONCOLOGY INC. (CA) 2024-01-18 — — US disclosed
EP-4229067-A1 METTL3 MODULATORS Accent Therapeutics, Inc. (US) 2023-08-23 — — EP disclosed
WO-2023110138-A1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2023-06-22 — — WO disclosed
US-20150203535-A1 DERIVATIVES OF PYRIDINONE AS INHIBITORS FOR TISSUE TRANSGLUTAMINASE ZEDIRA GMBH (DE) 2015-07-23 — — US disclosed
EP-2797892-B1 PYRIDINONE DERIVATIVES AS TISSUE TRANSGLUTAMINASE INHIBITORS ZEDIRA GMBH (DE) 2015-05-27 — — EP disclosed
EP-2797892-B1 PYRIDINONE DERIVATIVES AS TISSUE TRANSGLUTAMINASE INHIBITORS ZEDIRA GMBH (DE) 2015-05-27 — — EP disclosed
EP-2797892-A1 PYRIDINONE DERIVATIVES AS TISSUE TRANSGLUTAMINASE INHIBITORS Zedira GmbH (DE) 2014-11-05 — — EP disclosed
WO-2014012858-A1 PYRIDINONE DERIVATIVES AS TISSUE TRANSGLUTAMINASE INHIBITORS ZEDIRA GMBH (DE) 2014-01-23 — — WO disclosed
EP-2687511-A1 Pyridinone derivatives as tissue transglutaminase inhibitors Zedira GmbH (DE) 2014-01-22 — — EP disclosed
US-8471063-B2 Michael systems as transglutaminase inhibitors ZEDIRA GMBH (DE) 2013-06-25 — — US disclosed
US-8178490-B2 Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof REMPEX PHARMACEUTICALS, INC. (US) 2012-05-15 — — US disclosed
US-20110229568-A1 MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS ZEDIRA GMBH (DE) 2011-09-22 — — US disclosed
CN-101563359-A Michael systems as transglutaminase inhibitors ZEDIRA GMBH (DE) 2009-10-21 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150203535-A1 DERIVATIVES OF PYRIDINONE AS INHIBITORS FOR TISSUE TRANSGLUTAMINASE PLPBP, PNPO, PDXK CYP1A2 223/4885CYP2C9 58/4885CYP2C19 28/4885
US-20240051985-A1 METTL3 MODULATORS METTL3, METTL16, METTL14 CYP1A2 1036/4885CYP2C9 1003/4885CYP2C19 1902/4885
US-20240018110-A1 RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN KLK3, FOLH1, TMEM14C CYP1A2 4564/4885CYP2C9 4819/4885CYP2C19 4636/4885
US-20110229568-A1 MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS TGM2, TGM3, TGM1 CYP1A2 4301/4885CYP2C9 2482/4885CYP2C19 2652/4885
US-20260001914-A1 MACROCYCLIC PEPTIDES TARGETING KRAS KRAS, NRAS, HRAS CYP1A2 4664/4885CYP2C9 4428/4885CYP2C19 4701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.